Hai Xiang Pharmaceutical (002099.SZ) released its half-year performance report, with a net profit attributable to the parent company of 14.09 million yuan, a decrease of 63.01%.

date
29/08/2025
The Zhongtong Finance APP reported that Haixiang Pharmaceutical (002099.SZ) released its 2025 semi-annual report, with the company's operating income at 925 million yuan, a decrease of 10.94% year on year. The net profit attributable to shareholders of the listed company was 14.0937 million yuan, a decrease of 63.01% year on year. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 19.2833 million yuan, a decrease of 37.50% year on year. The basic earnings per share was 0.01 yuan.